Regeneron Pharmaceuticals PT Raised to $390.00 at Brean Capital (REGN)
Analysts at Brean Capital increased their price objective on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $380.00 to $390.00 in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the stock. Brean Capital’s price objective points to a potential upside of 11.28% from the company’s current price.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 4.29% on Tuesday, hitting $365.49. The stock had a trading volume of 1,029,988 shares. Regeneron Pharmaceuticals has a 52-week low of $245.99 and a 52-week high of $354.79. The stock’s 50-day moving average is $328.2 and its 200-day moving average is $312.7. The company has a market cap of $36.692 billion and a P/E ratio of 99.73.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings data on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.15 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $350.31, for a total value of $700,620.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. They now have a $310.00 price target on the stock. Separately, analysts at Credit Suisse raised their price target on shares of Regeneron Pharmaceuticals from $340.00 to $400.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Regeneron Pharmaceuticals from $389.00 to $436.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $354.11.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.